GlaxoSmithKline and Sanofi report strong results in trials of Covid vaccine

News will offer some some relief for GSK chief Emma Walmsley, who has been under pressure from investor

GlaxoSmithKline is in the running to bring a new Covid-19 vaccine on to the market by the year end, thanks to positive results from early trials that will allow the formula to enter into late-stage studies within weeks.

The news will offer some relief for GSK as it plays catchup with rivals, and to its chief executive, Emma Walmsley, who has come under pressure since activist investor Elliott Management took a sizeable stake in the company in April.

The vaccine, created with its French partner, Sanofi, was originally expected to gain regulatory approval in the first half of 2021, but was delayed in December after it failed to produce a strong immune response in older people.

GSK said on Monday interim results from a phase 2 trial showed a “strong neutralising antibody response” in all adult age groups, and raised no safety concerns, clearing the way to move to phase 3.

“We believe that this vaccine candidate can make a significant contribution to the ongoing fight against Covid-19 and will move to phase 3 as soon as possible to meet our goal of making it available before the end of the year,” Roger Connor, the president of GSK’s vaccines arm, said.

The vaccine uses similar technology deployed in Sanofi’s seasonal flu vaccine, and will be used alongside a so-called adjuvant created by GSK, which will act as a booster to the jab.

The phase 3 trial is expected to start in the coming weeks and involve 35,000 adults from a wide range of countries. It will also assess the efficacy of two vaccine formulas against variants that first emerged in Wuhan (D614) and South Africa (B.1.351). The pharmaceuticals firm said it hoped to gain regulatory approval for the vaccine in the fourth quarter of the year.

“Our phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases,” said Thomas Triomphe, the executive vice-president and head of Sanofi Pasteur, the company’s vaccine unit.

The UK had pre-ordered 60m doses of the GSK/Sanofi vaccine as of December.

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

The phase 3 trial announcement could give GSK more confidence to push back against American hedge fund Elliott Management.

The activist investor, which is known for waging aggressive campaigns for change at companies including BHP and Premier Inn owner Whitbread, took a multibillion-pound stake in the company last month. However, Elliott’s intentions at GSK are still unclear.

GSK shares were down 0.3% on Monday at £13.66 each.


Kalyeena Makortoff

The GuardianTramp

Related Content

Article image
GSK and Sanofi to start human trials of potential Covid-19 vaccine
World’s largest vaccine makers to begin testing on people in US with eye on rollout in early 2021

Joanna Partridge

03, Sep, 2020 @7:45 AM

Article image
GSK and Medicago report positive Covid vaccine trial data
Announcement follows encouraging news from collaboration with French drugmaker Sanofi

Julia Kollewe

18, May, 2021 @1:33 PM

Article image
GlaxoSmithKline faces dose of strong medicine from US investor
This week’s lacklustre results will strengthen boss Emma Walmsley’s case for reform – but also inspire her critics

Julia Kollewe

24, Apr, 2021 @11:05 PM

Article image
GlaxoSmithKline makes bold move with £130m Covid-19 investment | Nils Pratley
GSK’s share price has been left standing by AstraZeneca’s high-risk success in cancer treatments

Nils Pratley

20, Jul, 2020 @6:46 PM

Article image
GSK and CureVac sign £132m deal to develop multi-variant Covid vaccine
Companies hope to have next generation of vaccines against emerging variants by next year

Mark Sweney and Julia Kollewe

03, Feb, 2021 @10:41 AM

Article image
GSK/Sanofi Covid vaccine delayed until end of next year
Trials reveal vaccine failed to produce a strong immune response in older people

Ian Sample Science editor

11, Dec, 2020 @11:35 AM

Article image
GSK buys £130m stake in German coronavirus vaccine maker
Stake of 10% in CureVac is part of deal that could eventually be worth more than £800m

Jasper Jolly

20, Jul, 2020 @2:49 PM

Article image
GSK/Sanofi Covid booster delayed by lack of uninfected people to test it on
Early trials show jab effective in people of all ages who have already received doses of any vaccine

Julia Kollewe

15, Dec, 2021 @5:40 PM

Article image
AstraZeneca expands Covid-19 vaccine deal as final trials begin
UK drugmaker and Oxford Biomedica to produce more of potential coronavirus product

Julia Kollewe

01, Sep, 2020 @8:26 AM

Article image
GSK tells UK staff: turn off Covid test-and-trace app while at work
Drugs company says infection controls at some of its sites are so secure the app is not needed

Rob Davies

06, Oct, 2020 @5:36 PM